Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05411809

The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer

Stereotactic Body Radiation Therapy Clinical Trial

Official title:
The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer

Clinical Trial Summary

The purpose of this study is to determine whether ctDNA could help to evaluate whether to use drug adjuvant therapy after SBRT in patients with early lung cancer.

Clinical Trial Description

This is a prospective study. The purpose of this study is to determine whether MRD could help to evaluate whether to use drug adjuvant therapy after SBRT in patients with early lung cancer. The ctDNA was detected for early stage lung cancer patients before and after SBRT. If a high level of ctDNA was detected after SBRT, the patients were randomly divided into observation group and adjuvant treatment group. ;

Study Design

Related Conditions & MeSH terms

  • Stereotactic Body Radiation Therapy
Clinical Trial Details
NCT number NCT05411809
Study type Interventional
Source Peking University Third Hospital
Contact Hongqing Zhuang
Phone 82264910
Email hongqingzhuang@163.com
Status Not yet recruiting
Phase N/A
Start date June 15, 2022
Completion date May 15, 2027
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04161287 - Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE
Suspended NCT04020276 - OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases Phase 1
Recruiting NCT04940936 - Shared Decision Making on Radiation Dose for Lung Malignancies N/A
Recruiting NCT05189054 - Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
Not yet recruiting NCT04351282 - SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma N/A
Recruiting NCT03253536 - Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma N/A
Withdrawn NCT03431415 - Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer N/A
Recruiting NCT05209243 - START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC N/A
Recruiting NCT02545751 - SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer Phase 2
Completed NCT04912128 - Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases in NSCLC
Completed NCT03340974 - Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04147728 - Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC Phase 2
Recruiting NCT04512846 - Comparison of Efficacy in SBRT of Large HCC With or Without TACE